Drug Trial Radar · NCT06908226
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
324
Planned (sponsor's estimate)
Start
Feb 12, 2025
Primary completion
Nov 11, 2027
Study completion Dec 17, 2027
Sponsor
- Lead sponsor
- Longboard PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 66 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
Conditions
- Developmental and Epileptic Encephalopathy
Interventions
LP352Drug
LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) and AEs leading to discontinuationTime frame: Up to 61 Weeks
- Number of Participants With Clinically Significant Changes in Chemistry parametersTime frame: Up to 61 Weeks
- Number of Participants With Clinically Significant Changes in Hematology parametersTime frame: Up to 61 Weeks
- Number of Participants With Clinically Significant Changes in UrinalysisTime frame: Up to 61 Weeks
- Number of participants with clinically significant changes in vital signsTime frame: Up to 61 Weeks
- Number of participants with clinically significant changes in physical examinationsTime frame: Up to 61 Weeks
- Number of participants with clinically significant changes in growth parametersTime frame: Up to 61 Weeks
- Number of participants with clinically significant changes in electrocardiogram (ECG) parametersTime frame: Up to 61 Weeks
- Number of participants with postive responses to Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 61 Weeks
- Number of participants with positive responses to Patient Health Questionnaire-9 (PHQ-9) and Question 9Time frame: Up to 61 Weeks
Locations
88 sites in 17 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital - Cardiology Clinic
Little Rock, Arkansas
University of California Los Angeles (UCLA) - David Geffen School of Medicine - Global Health Pro...
Los Angeles, California
Stanford University - Stanford School of Medicine - Pulmonary and Cystic Fibrosis Center
Palo Alto, California
UCSF Benioff Children's Hospitals - San Francisco
San Francisco, California
Children's Hospital Colorado - Heart Institute
Aurora, Colorado
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida
University of Miami Medical Group (UMMG)
Miami, Florida
Research Institute of Orlando LLC
Orlando, Florida
Pediatric Epilepsy & Neurology Specialists (PENS)
Tampa, Florida
University of South Florida (USF) - Tampa Campus
Tampa, Florida
Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho
University of Iowa Health Care Medical Center (University of Iowa Hospitals & Clinics)
Iowa City, Iowa
Mid-Atlantic Epilepsy and Sleep Center - Bethesda
Bethesda, Maryland
Massachusetts General Hospital (MGH)
Boston, Massachusetts
Mayo Clinic - Children's Center - Rochester
Rochester, Minnesota
Barnabas Health - Institute of Neurology and Neurosurgery
Livingston, New Jersey
Northeast Regional Epilepsy Group - Morristown
Morristown, New Jersey
NYU Langone Health-NYU Comprehensive Epilepsy Center
New York, New York
Oregon Health & Science University - Blood Brain Barrier and Neuro-Oncology Program
Portland, Oregon
Child Neurology Consultants of Austin - Austin
Austin, Texas
The University of Texas Medical School at Houston - UT Gastroenterology
Houston, Texas
Sydney Children's Hospital - Randwick
Randwick, New South Wales, Australia
The Children's Hospital-Westmead - Heart Centre for Children
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital (RBWH)
Brisbane, Queensland, Australia
Queensland Children's Hospital (Lady Cilento Children's Hospital)
Brisbane, Queensland, Australia
Austin Hospital
Heidelberg, Victoria, Australia
The Royal Children's Hospital (RCH) Melbourne
Parkville, Victoria, Australia
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, Antwerp, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Flemish Brabant, Belgium
Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de Medicina (HCFMUSP) - Inst...
São Paulo, Brazil
Instituto de Neurologia de Curitiba (INC)
Curitiba, Paraná, Brazil
Moinhos de Vento Hospital (Hospital Moinhos de Vento) (HMV)
Porto Alegre, Rio Grande do Sul, Brazil
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
Peking University First Hospital (Beida Hospital)
Beijing, Beijing Municipality, China
Capital Medical University-Beijing Children's Hospital
Beijing, Beijing Municipality, China
Guangzhou Medical University-The Second Affiliated Hospital
Guangzhou, Guangdong, China
Shenzhen Children's Hospital
Shenzhen Shi, Guangdong, China
Wuhan Children's Hospital
Wuhan, Hubei, China
Fudan University - Children's Hospital
Shanghai Shi, Shanghai Municipality, China
AP-HM- Hôpital de La Timone
Marseille, France
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.